Results 191 to 200 of about 133,125 (289)

Personalized Nutrition and the Regulatory Framework - Moving Forward. [PDF]

Adv Nutr
Bremer AA.
europepmc   +1 more source

Editorial: Sudden Unexpected Death in Epilepsy: Bio-markers, Mechanisms, Risk Identification and Prevention. [PDF]

, 2019
DeGiorgio, Christopher M., Sperling, Michael R., Surges, Rainer   +2 more
core   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Long‐term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real‐world cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta, Luigi Angelo Fiorito, Roberta Vescovo, Anna Virgilio, Giulia Amato, Giuseppe Cimino   +5 more
wiley   +1 more source

Energy expenditure measurement in critical care: Implications for personalized nutrition support. [PDF]

World J Crit Care Med
Chen J, See KC.
europepmc   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

Personalized Nutrition Biomarkers and Dietary Strategies for Atherosclerosis Risk Management: A Systematic Review. [PDF]

Nutrients
Fayyaz K, Din MSU, Bashir H, Ahmad F, Barrow CJ, Khalid N.   +5 more
europepmc   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source

Genome-wide association meta-analysis of fish and EPA+DHA consumption in 17 US and European cohorts [PDF]

, 2017
Borecki, Ingrid B, et al.,, Wojczynski, Mary K   +2 more
core   +1 more source

Harnessing Cellular Feeling: Epigenetic to Mechanical Memory as a Framework for Stem Cell Manufacturing

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Stem cell‐based therapies hold transformative potential for regenerative medicine, yet their progress is constrained by persistent variability in manufacturing and clinical performance. Conventional frameworks such as Quality by Design (QbD), though effective for drugs and biologics, struggle to accommodate the dynamic nature of living cell ...
Mee‐Hae Kim, Masahiro Kino‐oka
wiley   +1 more source